Validatedin vitro/in vivocorrelation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times-Reference-Cited by-同舟云学术

Validatedin vitro/in vivocorrelation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times

Published:2012-10 Issue:12 Volume:8 Page:1495-1503
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Mundin Gill E,Smith Kevin J,Mysicka Jana,Heun Gerhard,Krämer Mathias,Hahn Udo,Leuner Christian

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425255.2012.729578

Reference21 articles.

1. Opioid-Induced Bowel Dysfunction

2. Opioid-induced bowel dysfunction in cancer-related pain: Causes, consequences, and a novel approach for its management

3. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers

4. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral controlled release dosage forms: dissolution versus diffusion;Expert Opinion on Drug Delivery;2020-04-20

2. Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients – a randomized trial;Journal of Drug Assessment;2020-01-01

3. Slow drug delivery decreased total body clearance and altered bioavailability of immediate‐ and controlled‐release oxycodone formulations;Pharmacology Research & Perspectives;2016-01-22

4. In vitro–in vivocorrelations: general concepts, methodologies and regulatory applications;Drug Development and Industrial Pharmacy;2015-07-02

5. How-To: Empirical IVIVR Without Intravenous Data;Dissolution Technologies;2015